- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05981846
Een fase II-onderzoek om de veiligheid en immunogeniciteit van BIMERVAX® te evalueren bij gelijktijdige toediening met seizoensgriepvaccin (SIIV) bij volwassenen ouder dan 65 jaar die volledig zijn gevaccineerd tegen COVID-19
Een gerandomiseerde, dubbelblinde, multicentrische fase II-studie om de veiligheid en immunogeniciteit van BIMERVAX® te evalueren bij gelijktijdige toediening met seizoensgebonden oppervlakte-antigeen, geïnactiveerd griepvaccin met adjuvans (SIIV) bij volwassenen ouder dan 65 jaar die volledig zijn gevaccineerd tegen COVID -19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
In this study approximately 300 adults aged 65 or older will be enrolled and followed for 1 month after study treatment. Safety and immunogenicity of all participants will be assessed.
The participants will be randomised 1:1:1 to one of the following three cohorts:
- Cohort 1: approximately 100 participants will receive one dose of SIIV in one arm + one dose of placebo in the other arm, at Day 0.
- Cohort 2: approximately 100 participants will receive one dose of BIMERVAX® in one arm + 1 dose of placebo in the other arm, at Day 0.
- Cohort 3: approximately 100 participants will receive one dose SIIV in one arm + one dose of BIMERVAX® in the other arm, at Day 0.
All participants will receive two administrations at Day 0 and will be followed for 1 month. All subjects will be closely observed for 15 minutes after vaccination on site. The study will be double-blind, both the participant and the physician (care provider) will be blinded. Participants will be provided with a participant paper diary on Day 0 to record solicited local and systemic reactions after vaccination through Day 7. Unsolicited local and systemic adverse events, SAEs and AESIs, will be recorded through Day 28 (end of study).
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
A Coruña
-
A Coruña, A Coruña, Spanje, 15011
- Hospital HM Modelo
-
Santiago de Compostela, A Coruña, Spanje, 15706
- Hospital Clínico Universitario de Santiago
-
-
Barcelona
-
Badalona, Barcelona, Spanje, 08916
- Hospital Germans Trias i Pujol
-
Barcelona, Barcelona, Spanje, 08036
- Hospital Clínic de Barcelona
-
Centelles, Barcelona, Spanje, 08540
- CAP Centelles
-
-
Girona
-
Girona, Girona, Spanje, 17001
- Hospital Josep Trueta
-
-
Málaga
-
Málaga, Málaga, Spanje, 29010
- Hospital Regional de Málaga
-
-
Valladolid
-
Valladolid, Valladolid, Spanje, 47003
- Hospital Clínico de Valladolid
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Adults aged 65 or older at Day 0.
-
Are willing and able to sign the informed consent and can comply with all study visits and procedures.
-
Participant must have received at least a primary scheme of an mRNA vaccine (2 doses). Booster doses or previous COVID-19 infections are allowed. Last dose must have been administered at least 6 months before Day 0. History of COVID-19 infection is allowed if occurred at least >30 days before Day 0.
-
Have a negative Rapid Antigen Test (RAT) at Day 0 before vaccinations.
-
Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with pre-existing chronic and stable diseases (non-immunocompromised), if these are stable and well-controlled according to the investigator's judgment.
Exclusion Criteria:
-
Acute illness with fever ≥ 38.0°C at Day 0 or within 24 hours prior to vaccination. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
-
Allergy to egg proteins (egg or egg products) or chicken proteins.
-
History of Guillain-Barré syndrome (GBS)
-
History of COVID-19 infection (described as a positive RAT or PCR), in the previous 30 days before Day 0.
-
Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
-
History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s).
-
Immunocompromised individuals defined as those with primary and secondary immune deficiencies and those receiving chemotherapy or immunosuppressant drugs other than steroids and glucocorticoids (maximum 30mg/day of prednisone, or equivalent, by any administration route for a maximum of 30 consecutive days), within 90 days prior to vaccination or during the study.
-
Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
-
Receipt of blood-derived immune globulins, blood, or blood-derived products in the past 3 months.
-
Participation in other studies involving study intervention within 28 days prior to screening and/or during study participation.
-
Received any non-study vaccine within 14 days before or after screening. For live or attenuated vaccines, 4 weeks before or after screening.
-
History of a diagnosis or other conditions that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: BIMERVAX + SIIV
|
One dose of booster vaccine One dose |
|
Actieve vergelijker: BIMERVAX + PLACEBO
|
One dose of booster vaccine |
|
Actieve vergelijker: SIIV + PLACEBO
|
One dose |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.
Tijdsspanne: Day 0, Day 7
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7
|
|
Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through the end of the study.
Tijdsspanne: Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
|
Number and percentage of serious adverse events (SAEs) through the end of the study.
Tijdsspanne: Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
|
Number and percentage of adverse events of special interest (AESI) through the end of the study
Tijdsspanne: Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Total binding antibody titers against SARS-CoV-2 RBD at Days 0 and 28
Tijdsspanne: Day 0, Day28
|
To determine and compare the immunogenicity measured by means of total antibodies against the Receptor Binding Domain of the Spike protein of SARS-CoV-2, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV. |
Day 0, Day28
|
|
Geometric mean fold rise in total binding antibody titers against SARS-CoV-2 RBD at Day 28
Tijdsspanne: Day 0, Day28
|
To determine and compare the geometric mean fold rise (GMFR) in total binding antibody titers against the Receptor Binding Domain of the Spike protein of SARS-CoV-2 from Baseline to Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV. |
Day 0, Day28
|
|
Influenza strain-specific HAI antibody titers at Days 0 and 28
Tijdsspanne: Day 0, Day28
|
To determine and compare the immunogenicity measured by influenza strain-specific antibody titers using a haemagglutination inhibition (HAI) assay at Baseline and Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX® |
Day 0, Day28
|
|
Geometric mean fold rise in influenza strain-specific HAI antibody titers at Day 28
Tijdsspanne: Day 0, Day28
|
To determine and compare the geometric mean fold rise (GMFR) in influenza strain-specific antibody titers measured by haemagglutination inhibition (HAI) assay from Baseline to Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX®. |
Day 0, Day28
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Teresa Prat, Hipra Scientific, S.L.U
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HIPRA-HH-11
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .